Boston Scientific BSX saw continued strength in its Interventional Cardiology and Vascular Therapies (“ICVT”) business in the second quarter of 2026, with sales up 15% year over year. Interventional Cardiology led the performance, benefiting from double-digit growth in coronary therapies, with continued strength in Drug-Coated Balloon, imaging and complex Percutaneous Coronary Intervention. Management expects ICVT to be Boston Scientific’s strongest growth drivers in the coming years.
In May, the company presented data from the FRACTURE trial, studying its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter, in a late-breaking trial session at the EuroPCR 2026 congress. The trial met all endpoints, demonstrating high rates of freedom from major adverse cardiac events at 30 days and procedural success in patients with severely calcified coronary artery disease. Boston Scientific expects to launch the device in the first half of 2027.
The company also invested nearly $1.5 billion for an approximately 34% equity stake in MiRus LLC, developer of the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (“TAVR”) system. This agreement includes an exclusive option to acquire the MiRus TAVR system, subject to additional payments and certain milestones. Backed by years of research and proprietary technology, the SIEGEL valve’s unique design and impressive early clinical results may set it apart from currently available technologies.
In addition, enrollment is advancing in the THRIVE trial, which is evaluating the TIVUS Ultrasound System for renal denervation in the treatment of hypertension. The technology is expected to reach the market in 2028. Meanwhile, Vascular Therapies sales were led by broader adoption of Varithena and the drug-eluting portfolio. The SEISMIQ peripheral IVL launch is gaining a strong reception for its clinical differentiation as supply continues to ramp up.
The pending Penumbra acquisition could further expand BSX’s opportunities. The deal is nearing completion, subject to remaining regulatory clearances, and is expected to bolster the company’s long-term growth profile.
BSX Peer Update
Medtronic MDT is investing approximately $700 million in Cornerstone Robotics as it expands presence in surgical robotics. Under the partnership, Medtronic will distribute Cornerstone’s Sentire system in select markets outside the United States where it has regulatory approval, alongside its own Hugo robotic-assisted surgery system. Medtronic also announced a strategic investment in Pi-Cardia Ltd., under which it will invest up to $80 million and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027.
Stryker SYK has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength. The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.
BSX Price Performance, Valuation and Estimates
Year to date, Boston Scientific’s shares have plunged 50.7% compared with the industry’s 16.6% decline.
Image Source: Zacks Investment Research
Boston Scientific currently trades at a forward, five-year Price-to-Sales (P/S) ratio of 3.09, above the industry average of 2.24.
Image Source: Zacks Investment Research
The company’s earnings estimates have been steadily revised downward over the past three months.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).